News Human Gut Microbes May Help Suppress MS, New Research Suggests Human Gut Microbes May Help Suppress MS, New Research Suggests by Patricia Inacio, PhD | August 14, 2017 Share this article: Share article via email Copy article link A bacteria presentĀ in the gut, called Prevotella histicola, preventedĀ multiple sclerosis (MS) from developing in a preclinical mouse model, foundĀ researchers at the Mayo ClinicĀ inĀ Rochester, Minnesota, along with colleagues at the University of Iowa. Their study, āHuman Gut-Derived Commensal Bacteria Suppress CNS Inflammatory and Demyelinating Disease,ā appeared in the journal Cell Reports. CurrentĀ research suggests that alterations to the gut microbiome residing in human intestines may potentially triggerĀ inflammatory diseases such as MS. In an attempt to identify which gut resident bacteria are capable of modulating immune responses, researchers studiedĀ cultured small pieces of intestine tissue extracted fromĀ biopsies of patients with celiac disease. The team then isolated three bacteria strains and found that one of species āĀ P. histicolaĀ ā had the capacity to suppress MS in a preclinical animal model of the disease. āThis is an early discovery but an avenue that bears further study,” Dr. Joseph Murray, a Mayo Clinic gastroenterologist and the study’s lead author, said in a press release.Ā “If we can use the microbes already in the human body to treat human disease beyond the gut itself, we may be onto a new era of medicine. We are talking about bugs as drugs.” By investigating how P. histicola modulated immune responses to suppress MS, researchers found that bacteria decreased the expression of two pro-inflammatory cytokines ā interferon-gamma and interleukin (IL)-17. OverallĀ results show thatĀ P. histicola has immune modulatory activity and can suppressĀ abnormal immune responses, which ultimately prevent autoimmunity. ThisĀ supports the idea that maintaining a healthy microbial community within our intestines is a potential therapeutic strategy for MS. “Our work is a classic example of a bedside-to-bench and potentially back to bedside study. Recent MS microbiome studies have shown the lack of Prevotella genus in patients with the disease and an increase when patients were treated with disease-modifying drugs,” said Ashutosh Mangalam, the study’s first author and an assistant professor of pathology at University of Iowa’s Carver College of Medicine.Ā “And it’s not just for MS, because this may have a similar modulating effect on other nervous system andĀ autoimmune diseases.” Print This Page About the Author Patricia Inacio, PhD Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship. Tags gut microbiome, IL-17, immune system, inflammation
April 22, 2024 News by Marisa Wexler, MS AAN 2024: Briumvi found to ease disability in certain MS patients
April 22, 2024 Columns by Desiree Lama Learning to manage cognitive impairment with multiple sclerosis
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Earlier Ocrevus lowers MS progression risk over 10 years